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Abstract
The quantitative determination of the expression of CD20 and CD52 antigens in chronic lymphocytic leukemia
(CLL) is important for treatment with monoclonal antibodies (mAbs). Patients with CLL in complete or partial
remission have a higher level of CD52 antigen expression compared with patients with CLL untreated, in
progression, or diagnosed with small lymphocytic lymphoma (SLL). Our results support the possible signiﬁ-
cance of alemtuzumab consolidation.
Background: Rituximab and alemtuzumab, mAbs used in recent years to treat CLL, are directed against antigens
CD20 and CD52. CD20 is not highly expressed by CLL tumor cells, and rituximab does not have signiﬁcant effec-
tiveness in CLL unless combined with chemotherapy. Alemtuzumab targets CD52, which is much more highly
expressed, and is currently the most effective agent used alone for CLL. Variability in expression of both antigens
among these patients might be related to different individual therapeutic responses to mAb therapy. Patients and
Methods: A total 95 patients diagnosed with CLL and/or SLL were divided into 4 groups: (1) untreated; (2) in complete or
partial remission; (3) disease in progression; and (4) diagnosedwithSLL. Flowcytometry of peripheral blood cells included
gatingof theCD5þCD19þ tumorpopulation,withinwhichmeanﬂuorescence intensity ofﬂuorescein isothiocyanate (FITC)
conjugatedwith anti-CD20or anti-CD52antibodywasmeasured. The resulting expression of the2 antigenswasdeduced
from thecalibration curve usingQuantumFITCparticles.Results: Expression of CD20 showed no signiﬁcant differences
among the 4 groups of patients. However, signiﬁcantly greater expression of surface antigen CD52 was recorded in
patient group 2 in complete or partial remission (P < .001). Conclusion: The residual population of CLL cells after
therapy is characterized by increased surface detection of CD52. Although the exact cause of this phenomenon is
unknown, our results provide a basis to consider the potential for CLL consolidation therapy using alemtuzumab.
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Despite considerable progress in its therapy in recent years,1
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Table 1 Characteristics of Patients (n [ 95)
Characteristic Value
Median Age (Range), Years 63 (39-87)
Sex, n
Male 58
Female 37
Untreated Patients
Newly diagnosed 20
Monitored 17
Patients in CR/PR
CR 18
PR 3
Patients in Disease Progression
1 Previous therapy 8
2 Previous therapies 11
Small Lymphocytic Lymphoma 18
Figure 1 (A) CD52 Antibody Titering on CLL Cells. 2 3 105
Leukocytes in the Total Volume of 100 mL. CLL Cells
are Saturated Using 5 mL of FITC-Conjugated Anti-
CD52 Monoclonal Antibody. (B) Determining the
Linearity of a Flow Cytometer Ampliﬁcation System23
Abbreviations: CLL ¼ Chronic Lymphocytic Leukemia; FITC ¼ Fluorescence Intensity of
Fluorescein Isothiocyanate; MFI ¼ Mean Fluorescence Intensity.
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412 -surface of CLL cells are the targets for the therapeutic activities of
monoclonal antibodies. If rituximab (an anti-CD20 antibody) in
combination with chemotherapy or alemtuzumab (an anti-CD52
antibody) in monotherapy is used in ﬁrst-line CLL treatment, the
therapeutic responses achieved are in the range of 83% to 95%.2-4
The antigen CD20 is a classic marker of B-lymphocytes.5 CD20
is a phosphoprotein with 4 transmembrane domains and both of its
ends extend into the cytoplasm.6 Outside the plasma membrane
there are 2 loops of protein, 1 large and 1 small. It is believed that
CD20 acts as a store-operated calcium channel, which is signiﬁcant
for the cell homeostasis of calcium and for passage through the cell
cycle.7,8 In contrast to other B-lymphoproliferative diseases, the
expression level of CD20 in CLL is low.9
CD52 is expressed by cells within the immune system (lym-
phocytes, monocytes, macrophages, and eosinophils) and by cells of
the epididymal tissue in the male genital tract.10 CD52 is a glyco-
peptide whose peptide chain is composed of just 12 amino acids.11
The greater part of the molecule consists of the side hydrocarbon
complex bound outside the plasma membrane. The C-terminus of
the peptide chain is loosely bound to the outer layer of the cell
membrane by a glycosylphosphatidylinositol lipid (GPI) anchor.
The GPI anchor is a posttranslational modiﬁcation common to a
group of proteins typically constituting a component of lipid rafts.12
Lipid rafts are sphingolipid- and cholesterol-enriched membrane
microdomains.13 Proteins with a GPI anchor might spontaneously
transfer from one cell and incorporate themselves into the cell
membrane of a different cell.12 The function of CD52 in the im-
mune system is not known, and its expression by CLL cells is lower
than that in, for example, either mantle cell lymphoma or normal
B-lymphocytes.14
We assume that in addition to cell cycle arrest and direct
apoptosis induction the effectiveness of the monoclonal antibodies
on tumor cells occurs through effector mechanisms of the immune
system, the necrosis-causing complement-dependent cytotoxicity
(CDC) and antibody-dependent cellular cytotoxicity (ADCC).
Although we know neither the complex working of these mecha-
nisms in vivo nor their role in individual compartments, studies
have been able to illustrate them separately in vitro. After binding to
rituximab, the CD20 molecule moves to lipid rafts, where it triggers
calcium inﬂux and cross-linking of surface-bound rituximab by a
secondary antibody, enhances a calcium inﬂux and signal trans-
duction, which leads to apoptosis.15 In contrast, the CD52 is
preferentially localized in lipid rafts and cross-linking of the bound
alemtuzumab on CLL cells leads to the formation of aggregates of
lipid rafts and induction of cell death.16 Even if this constitutes
merely a redistribution and increased local concentration of antigens
within the cell membrane caused by rituximab or artiﬁcially by the
secondary antibody, we can conclude that the more antigens that are
available for the lipid rafts, the more efﬁcient will be the effect
indirectly inducing apoptosis.
Nevertheless, it has been demonstrated that only in the presence
of a complement does in vitro lysis of CLL cells by rituximab
correlate with a quantitatively determined level of CD20 expres-
sion.17 The effect of the CDC is again related to the translocation of
the CD20 and rituximab complex into lipid rafts.18 Rituximab
binds to the large extracellular loop of CD20. The second-
generation anti-CD20 antibody ofatumumab, which has greaterClinical Lymphoma, Myeloma & Leukemia October 2014CDC activity than does rituximab, binds to the small loop closer to
the cell membrane.19 Alemtuzumab mediates CDC lysis of CLL
cells much more efﬁciently than does rituximab, probably because
of the much greater expression of CD52.20
Figure 2 Quantitatively Determined CD20 Expression in 4
Groups of Patients Based on MESF-FITC Units. There
Was No Signiﬁcant Difference Among the Patients
Abbreviations: CLL ¼ Chronic Lymphocytic Leukemia; FITC ¼ Fluorescence Intensity of
Fluorescein Isothiocyanate; MESF ¼ Molecules of Equivalent Soluble Fluorochrome; SLL ¼
Small Lymphocytic Lymphoma.
Michaela Pevna et alThe main mechanism mediating ADCC is probably the domi-
nant cytotoxic effect of natural killer cells. The ADCC effect of
rituximab does not differ among cell lines, despite differences in
CD20 expression.21 The level of CD52 expression is not proven to
be related to cell lysis via the ADCC mechanism after binding of
alemtuzumab.20
Patients and Methods
Patients
The study group consists of 95 patients diagnosed with CLL and/
or small lymphocytic lymphoma (SLL). Patients were divided into
4 groups: (1) CLL patients newly diagnosed or so far untreated;
(2) CLL patients minimal residual disease (MRD)-positive after
treatment in complete (CR) or partial (PR) remission22; (3) pre-
treated patients with CLL in progression; and (4) patients diagnosed
with SLL. Samples of peripheral blood were collected from patients
in each group. An overview of the patients is given in Table 1.
Sample Preparation
The sample of fresh peripheral blood containing 2  105 leu-
kocytes, with volume in microliters that we obtained from theTable 2 Median Expression Level in MESF-FITC Units for CD20 and
Antigen CLL, Untreated
CD20 34641.0
CD52 305961.5
CD5þCD19þ Population, % (Range) 88.46 (54.95-98.4)
Abbreviations: CLL ¼ chronic lymphocytic leukemia; MESF-FITC ¼ molecules of equivalent soluble
lymphoma.white blood cell (WBC) count (x ¼ 2  105/WBC count),
was ﬁlled to the volume of 100 mL using phosphate buffered
saline. The total volume of 100 mL for the diluted sample was
chosen (to include leukopenia patients after therapy) as a constant
volume and number of cells required to obtain the same default
reaction conditions for all of the samples. A reduction in the
number of cells to 2  105 leukocytes was determined on the basis
of the titration curve such that the total volume of the 100-mL
sample after adding 5 mL of ﬂuorescent-labeled monoclonal anti-
bodies against the target antigen would bring us to a saturating
concentration for all cells (Figure 1A).
The following antibodies were used to label the sample: anti-
CD19 antibody conjugated with R-phycoerythrin and anti-CD5
antibody conjugated with phycoerythrin-Cy5 (Invitrogen, Carls-
bad, CA) were used to identify the CLL population. Anti-CD20
and anti-CD52 antibodies conjugated with ﬂuorescein isothiocya-
nate (FITC; Invitrogen) were used to determine the level of
expression of the target antigens CD20 and CD52. The samples
were incubated for 20 minutes at room temperature, then lysed with
formic acid and osmolarity was then adjusted using a standard
protocol and ImmunoPrep Reagent System reagents (Beckman-
Coulter, Fullerton, CA).
Quantitative Fluorescence Cytometry
The samples were analyzed using a Cytomics FC500 (Beck-
man-Coulter). The system linearity was tested (Figure 1B).23 The
gating procedure in all 4 groups of patients involved gating of
lymphocytes on an forward scatter/side scatter (FS/SS) dot plot,
an exclusion of doublets and subsequently gating the
CD5þCD19þ population. Mean ﬂuorescence intensity (MFI) of
the target antigen CD20 or CD52 was determined from
a histogram. A total of 10,000 cells were measured at the
CD5þCD19þ gate. Quantum FITC-calibrated microparticles
with predetermined values of ﬂuorescence in molecules of
equivalent soluble ﬂuorochrome (MESF) units (Bangs Labora-
tories, Fishers, IN) were analyzed using the same protocol and the
same setting as those of the sample. The calibration curve was
made using Quick-Cal software (Bangs Laboratories) and the MFI
values of each peak of the calibrated values. Finally, the level of
expression of the target antigen in MESF units of ﬂuorochrome
FITC was deduced from the calibration curve.
Statistical Analyses
The nonparametric KruskaleWallis test was used for the
4 groups of patients. ManneWhitney U tests were subse-
quently made for every possible pair combination from the 4
groups.CD52 Antigens
CLL, CR/PR CLL, Progression SLL
27491.0 22606.0 31393.5
920386.0 296855.0 432269.0
27.8 (5.1-58.9) 81.57 (18.8-97.56) 40.7 (15.41-92.1)
ﬂuorochromeeﬂuorescence intensity of ﬂuorescein isothiocyanate; SLL ¼ small lymphocytic
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Table 3 Characteristics of Patients in CR or PR (n [ 21)
Characteristic Value
Median WBC Count (Range), 3 109/L 6.19 (2.93-10.6)
Median CD5þCD19þ Population in Gate of
Lymphocytes (Range), %
27.8 (5.1-58.9)
Median Time Interval From Last Therapy
(Range), Months
8 (1-59)
Last Therapy
FC 8
FCR 6
FC-O 1
Alemtuzumab 4
NA 2
IgVH Mutation Status
Mutated 1
Unmutated 15
NA 5
Abbreviations: FC ¼ ﬂudarabine with cyclophosphamide; FCR ¼ ﬂudarabine with cyclophos-
phamide and rituximab; FC-O ¼ ﬂudarabine with cyclophosphamide and ofatumumab; WBC ¼
white blood cell.
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Antigen CD20
The nonparametric KruskaleWallis test did not demonstrate
inhomogeneity in distribution of the values of the quantitatively
established CD20 among the 4 groups of patients. Also, the
ManneWhitney U test showed no difference in the distribution
of quantitatively determined CD20 values between any possible
pair from the 4 groups of patients. Most different from each other
were the groups 1 (patients with newly diagnosed or untreated CLL)
and 3 (pretreated patients with CLL in progression), but this dif-
ference was not statistically signiﬁcant (P < .076) (Figure 2,
Table 2). In the group 2 of patients in CR/PR at least 1 month
elapsed since the end of therapy that included anti-CD20 mono-
clonal antibody (in 7 of them).
CD52 Antigen
For the values of quantitatively determined CD52, the Krus-
kaleWallis test did demonstrate inhomogeneity in distribution of
the 4 monitored groups (P < .001). Subsequent analysis of the
individual groups using the ManneWhitney U test showed a
signiﬁcantly greater value of quantitatively determined CD52 an-
tigen (compared with each of the remaining groups) in group 2,
which were CLL patients MRD-positive after treatment in CR or
PR (P < .001) (Figure 3, Table 2). An overview of this group of
patients is shown in Table 3, and ﬂow cytometric analyses of pe-
ripheral blood from 1 of the patients are shown in Figure 4. There
was no signiﬁcant correlation between percentage of residual CLL
population and MESF values (Figure 5). Four of 21 patients in this
group received alemtuzumab during the last therapy, from which at
least 6 months passed. In 2 of these patients, 6 and 12 months after
the end of therapy, the measured values were 451,758 and 460,946Figure 3 Quantitatively Determined CD52 Expression Among
4 Groups of Patients in MESF-FITC Units. The Group
of Patients in Category CR/PR Differs Signiﬁcantly
From the Others (P < .001)
Abbreviations: CLL ¼ Chronic Lymphocytic Leukemia; FITC ¼ Fluorescence Intensity of
Fluorescein Isothiocyanate; MESF ¼ Molecules of Equivalent Soluble Fluorochrome; SLL ¼
Small Lymphocytic Lymphoma.
Clinical Lymphoma, Myeloma & Leukemia October 2014MESF-FITC for the CD52 antigen. The remaining 2 patients,
17 and 33 months after the last treatment, had greater quantitatively
determined values of CD52 antigen expression: 904,861 and
1,569,584 MESF-FITC. All of the patients in this group exhibited
an increasing proportion of the CD5þCD19þ cell population in the
gate of lymphocytes and showed progression of CLL in 3 years after
collection of the peripheral blood sample for the quantitative ﬂuo-
rescence cytometry analysis (data not shown).
The ManneWhitney U test showed a difference between groups
1 (patients with newly diagnosed or untreated CLL) and 4 (SLL)
(P < .03).
Discussion
To our knowledge, this is the ﬁrst report drawing attention to
increased surface detection of CD52 on CLL cells in patients after
treatment determined using quantitative ﬂuorescence cytometry
and, according to our data, the level of expression of CD20 did not
change in relation to treatment. Although quantitative ﬂuores-
cence cytometry is not yet a standardized method at the inter-
laboratory level, the MESF unit is now deﬁned by the National
Institute of Standards and Technology,24 and it is sufﬁcient to
analyze the variability of the surface expression of CD20 or CD52
within one lab.
A potential problem of our work lies in the fact that the results
from our group of patients with CLL after therapy might interfere
with the polyclonal physiological CD5þCD19þ B cell, because our
gating strategy of residual population is based on the CD5þCD19þ
population within the gate of lymphocytes. B1 cells are distin-
guished from conventional circulating B cells (B2) by their devel-
opmental origin, their surface marker expression, and their
functions.25,26 B1a cells are CD5-positive, and B1b cells are CD5-
negative. Physiological CD5þCD19þ cells dominate in the popu-
lation of B-lymphocytes during fetal life. Their ratio declines
with age, and in healthy adults the cells represent 10% to 25% of
Figure 4 Quantitative Fluorescence Cytometry in a Patient With MRD-Positive Complete Remission. (A) Initial FS/SS Dot Plot Used to
Gate Lymphocytes; (B) CD5DCD19D Population Gated on Lymphocytes, 2-Color Dot Plot; (C) MFI of the Target Antigen CD52
in Histogram Based on Channel FL1-FITC, Gated on CD5D19D Lymphocytes; (D) Standard Calibration Particles on FS/SS Dot
Plot; (E) 5 Peaks of Standard Particles in Histogram Based on Channel FL1-FITC; and (F) Calibration Curve Constructed From
MFI Values of Each Peak of Standard Particles. The Level of CD52 Expression in the Patient is 1,199,186 MESF-FITC
Abbreviations: FITC ¼ Fluorescence Intensity of Fluorescein Isothiocyanate; FS/SS ¼ Forward scatter/Side scatter; lin ¼ linear scale/channel; MESF ¼ Molecules of Equivalent Soluble Fluorochrome;
MFI ¼ Mean Fluorescence Intensity; MRD ¼ Minimal Residual Disease; PE ¼ phycoerythrin.
Michaela Pevna et alB-lymphocytes. In old age, their number increases again.27 Unlike
the protocol used by Rawstron et al to detect MRD in CLL,28
which is highly sensitive, the samples from our patients in CR/PR
contained more than 5% of CD5þCD19þcells in the gating of
lymphocytes. We believe there is signiﬁcant indirect evidence as to
the pertinence of the gated CD5þCD19þcells to the malignant
CLL population based on the fact that all patients in the CR/PR
group during a 3-year monitoring process showed an increasingtrend in the ratio of the CD5þCD19þ population to the gating of
lymphocytes. The patients in this group later showed a progression
of disease.
One explanation of our data is that only the part of CLL
cells with increased expression of CD52 antigen might survive
the therapy or the therapy might lead to the selection of cells
with an increased expression of CD52. It is of interest that
even after alemtuzumab therapy, the expression level of CD52Clinical Lymphoma, Myeloma & Leukemia October 2014 - 415
Figure 5 MESF Values Plotted Against Percentage of Residual
CD5D19D Population in Group 2
Abbreviation: MESF ¼ Molecules of Equivalent Soluble Fluorochrome.
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416 -on the residual CLL population is high in 2 of 4 patients in
our study.
Although the CD52-I isoform is sensitive to the lysing of
phosphatidylinositol-speciﬁc phospholipase C (PI-PLC), the
CD52-II isoform is resistant.29 Reduced degradation of the GPI
anchor in the case of isoform CD52-I using PI-PLC can also be
theoretically responsible for the upregulation of CD52 in the CLL
residual population. Proteins with a GPI anchor are subject to
internalization to a cell by a mechanism different than clathrin-
dependent endocytosis.30 The change of speed in the recycling of
proteins with a GPI anchor31 back to the membrane might be
revealed in the ﬁnal surface expression of these proteins.
Although the median levels of circulating CD20 and CD52 were
comparable,32,33 our results in groups 1 and 3 show the level of
surface antigen expression of CD52 on CLL cells in MESF-FITC
units to be 10 times higher than the level of CD20 expression. If
we take into account that the sources of the circulating antigens
consist only from cell apoptosis and CLL cell turnover, then the
relatively lower level of circulating CD52 with a view to its higher
surface expression might suggest a different cycle for the 2 antigens
in vivo. It appears that circulating CD52 antigen in the case that its
structure is intact has an increased afﬁnity for the membranes of
living cells and is retained by them (cell surface painting).12
Transfer of CD52 antigen is known within the male genital
tract, where it is released by the epithelial cells of distal epididymis
and ductus deferens into the seminal plasma and then acquired by
sperm cells, which do not express it.34 Many cells are broken down
during CLL therapy and acquisition of free CD52 antigen by the
residual population also can explain our data. This could explain
better progression-free survival (PFS) after ﬂudarabine and alem-
tuzumab combination treatment than after ﬂudarabine mono-
therapy.35 We can conclude that high expression of CD52 on the
residual CLL population, which persists according to our data for
several months, might be a consequence of increased expression,
reduced release or cleavage, and increased surface membrane
retention of this antigen.
Chronic lymphocytic leukemia is a disease with a variable clinical
course. New biological prognostic markers allow us to stratify pa-
tients into different risk groups at the time of diagnosis.36-39Clinical Lymphoma, Myeloma & Leukemia October 2014Patients achieving an MRD-negative CR survive longer without
progression (PFS) and, according to some analyses, have overall
survival as good as or better than patients who achieve MRD-
positive CR.4,40-42 In cases of CLL after allogeneic HSCT, which
now constitutes the only potentially curative CLL treatment, the
eradication of MRD is linked with a decreased risk of relapse.43
Although this treatment is based on different principles than is
the conventional therapy, and it is loaded with toxicity, it underlines
the importance of eliminating MRD in CLL for the long-term
success of the treatment. In particular, patients with unfavorable
prognostic markers might beneﬁt from the eradication of MRD.
A low level of circulating CD52 after CLL treatment using FCR
(ﬂudarabine, cyclophosphamide, and rituximab)44 and detection of
high expression of CD52 in the residual CLL population in our
patients after treatment appear to represent conditions suitable for
consolidation therapy using alemtuzumab, which already has been
examined in clinical studies.45-49 There is no known optimal
treatment scheme for consolidation therapy in the case of CLL
using alemtuzumab, and differences include the method of
administering alemtuzumab, the interval between the beginning of
the consolidation therapy and previous therapy, the maximum
single dose, and the duration of therapy in weeks. Improvement in
therapeutic response after consolidation using alemtuzumab varies
considerably among published studies and in a range of 15% to
66% of patients. Alemtuzumab is effective during consolidation in
eliminating CLL cells from the peripheral blood and bone marrow,
including MRD, and its effect on lymphadenopathy is less. In this
respect, we can state that circulating CD52, which is low after the
previous therapy,44 will not probably be the general cause of
alemtuzumab failure during lymphadenopathy. The infectious
complications might be fatal, and, in particular, reactivation of
cytomegalovirus infection and opportunistic infections45-48 are
limiting factors. However, our results indicate that high levels of
the surface CD52 on the residual population in CR patients lasts
for several months. Postponement of the consolidation using
alemtuzumab for a longer interval, which is necessary for the im-
mune reconstitution after therapy, might be important for at least
2 reasons. These are to reduce the risk of opportunistic infections
and for functioning of lymphokine-activated killer cells, which
play a key role in ADCC, becoming normal in 12 months after an
FCR regimen.50
Conclusion
The increased surface expression of CD52 antigen on the residual
CLL population after therapy, as detected in our study, apparently
indicates that the CD52 antigen can be surface-expressed in CLL in
varying degrees. Because of its unknown function, we cannot say
how the therapy should contribute to the induction of CD52 an-
tigen increased surface detection, or whether it is a characteristic of
the residual CLL population. An analysis of a larger study group
will be needed to clarify these issues. Quantitative ﬂuorescence
cytometry analysis draws attention51 in connection with clinical
decisions for treatment of CLL, although more data need to be
analyzed. One clinically important result of our work is that the
residual CLL population shows an increased number of target an-
tigens for therapeutic intervention using alemtuzumab. The elimi-
nation of these cells through alemtuzumab consolidation might be
Michaela Pevna et alassociated with improved PFS, as in MRD-negative CR. Although
alemtuzumab consolidation has already been tested in clinical trials,
which revealed its signiﬁcant side effects, this treatment is not
optimized in the indication of residual CLL population eradication.
According to our results, the advantageous increased expression of
CD52 antigen is detected on the residual population even after
several months; the implementation of the “watch and wait” strat-
egy and the initiation of alemtuzumab consolidation much later
after the last therapy could have a better effect as a result of the
repaired immune effector mechanisms, either in terms of the lower
incidence of infectious complications, or in the effectiveness of
passive immunotherapy.
Clinical Practice Points
 Increased expression of CD52 antigen on residual CLL cells after
therapy is a novel information; the cause of this phenomenon is
unknown.
 Antigen CD52 is the target site for therapeutic intervention
using alemtuzumab.
 Patients with CLL in MRD-negative CR have better PFS than
patients in MRD-positive CR.
 Consolidation with alemtuzumab to eradicate residual CLL
population was tested in clinical trials that showed serious in-
fectious complications.
 Increased expression of CD52 antigen on residual CLL popu-
lation is detected even after several months; delay in alemtuzu-
mab consolidation for a longer interval might have a better effect.Acknowledgments
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